🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "major milestone" in the battle against superbug strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million new cases per year. Notably increased rates are seen in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Results and Worldwide Availability

Based on findings published in a prominent scientific publication, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which involves an injection and a pill. The trial included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, GARDP has the ability to register and commercialise the drug in many regions with limited resources.

Doctors treating patients have voiced hope. Having a one-pill regimen like this is described as a "revolutionary step" for gonorrhoea control. This is deemed vital to reduce the burden of the disease for individuals and to halt the transmission of untreatable gonorrhoea around the world.